Jafron Biomedical Co Ltd (300529) — Strategic Asset Allocation Index
Jafron Biomedical Co Ltd (300529) has a Strategic Asset Allocation Index of 53.3% as of June 2023. Strategic assets (PP&E of CN¥1.73 Billion plus long-term investments of CN¥-) total CN¥1.73 Billion, measured against net assets of CN¥3.25 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Jafron Biomedical Co Ltd Strategic Asset Allocation Index (2011–2021)
This chart shows how Jafron Biomedical Co Ltd's Strategic Asset Allocation Index has evolved across 11 annual periods from 2011 to 2021. As of June 2023, the index stands at 53.3%, representing strategic assets of CN¥1.73 Billion against net assets of CN¥3.25 Billion CNY. Explore Jafron Biomedical Co Ltd cash conversion from operations to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Jafron Biomedical Co Ltd (2011–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Jafron Biomedical Co Ltd from 2011 to 2021, covering 11 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Jafron Biomedical Co Ltd stock valuation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 37.6% | CN¥1.27 Billion | CN¥1.27 Billion | CN¥- | CN¥3.38 Billion | ▲ +5.7 pp |
| 2020 | 32.0% | CN¥905.51 Million | CN¥905.51 Million | CN¥- | CN¥2.83 Billion | ▲ +2.5 pp |
| 2019 | 29.5% | CN¥639.63 Million | CN¥639.63 Million | CN¥- | CN¥2.17 Billion | ▼ -2.4 pp |
| 2018 | 31.8% | CN¥548.19 Million | CN¥457.62 Million | CN¥90.57 Million | CN¥1.72 Billion | ▲ +8.4 pp |
| 2017 | 23.4% | CN¥325.55 Million | CN¥325.55 Million | CN¥- | CN¥1.39 Billion | ▲ +0.3 pp |
| 2016 | 23.1% | CN¥273.32 Million | CN¥273.32 Million | CN¥- | CN¥1.18 Billion | ▼ -23.0 pp |
| 2015 | 46.1% | CN¥260.16 Million | CN¥260.16 Million | CN¥- | CN¥564.06 Million | ▲ +1.6 pp |
| 2014 | 44.5% | CN¥201.28 Million | CN¥201.28 Million | CN¥- | CN¥452.42 Million | ▲ +9.0 pp |
| 2013 | 35.5% | CN¥135.03 Million | CN¥135.03 Million | CN¥- | CN¥380.12 Million | ▲ +12.7 pp |
| 2012 | 22.8% | CN¥66.33 Million | CN¥66.33 Million | CN¥- | CN¥290.84 Million | ▲ +16.0 pp |
| 2011 | 6.8% | CN¥14.73 Million | CN¥14.73 Million | CN¥- | CN¥215.57 Million | — |